Document is current
Any future updates will be listed below
-
Authors
Miskowiak, Kamilla W. https://orcid.org/0000-0003-2572-1384
Ozenne, Brice
Kjærstad, Hanne L. https://orcid.org/0000-0001-7781-8853
Fisher, Patrick M. https://orcid.org/0000-0002-8115-0611
Beaman, Emily E. https://orcid.org/0000-0001-9457-562X
Dam, Vibeke H.
Ysbæk-Nielsen, Alexander T.
Knudsen, Gitte M. https://orcid.org/0000-0003-1508-6866
Kessing, Lars V.
Macoveanu, Julian
Frøkjær, Vibe G.
Sankar, Anjali
-
Funding
Funding for this research was provided by:
Lundbeckfonden (R279-2018-1145)
- License Information
-
More Information
Article History
Received: 12 June 2025
Revised: 2 November 2025
Accepted: 10 November 2025
First Online: 15 December 2025
Competing interests
: KWM has served as consultant for Janssen, and Angelini. BO states that part of his salary while working on this project was covered by a grant from Novo Nordisk A/S. HLK has served as a consultant for Lundbeck. VHD has served as lecturer for H. Lundbeck. GMK has served as consultant for Sanos, Onsero, Pangea Botanica, Gilgamesh, and Seaport, and additionally served as lecturer for Abbvie, Angelini and H. Lundbeck. LVK has within the last three years served as a consultant for Lundbeck and Teva. VGF has served as consultant for Sage therapeutics, and additionally as lecturer for H. Lundbeck, Janssen-Cilag, and Gedeon Richter. All other authors declare no conflict of interest.
